Breaking News Instant updates and real-time market news.

BMRN

BioMarin

$86.87

-1.08 (-1.23%)

16:02
10/13/16
10/13
16:02
10/13/16
16:02

BioMarin BMN 270 study enrollment approved by MHRA

BioMarin Pharmaceuticals announced that the Medicines and Healthcare Products Regulatory Agency in the United Kingdom approved continued enrollment into the open-label Phase 1/2 study of BMN 270, an investigational gene therapy treatment for severe hemophilia A. BioMarin had previously announced that after enrolling the first 9 patients in the study, that dosing of patients had been suspended due to observed increases in alanine aminotransferase levels that exceeded a pre specified threshold set by the company. Following study suspension, the company reviewed safety and efficacy data on the 9 patients with the MHRA, and based on its review, the MHRA approved resumption of the study. The agency also approved the company's proposed amendments to the study, which included eliminating the requirement for prophylactic corticosteroids and increasing potential additional enrollment from up to three additional patients to up to six additional patients. BioMarin intends to resume enrollment in the Phase I/2 study before the end of 2016. Based on protocol amendments, three patients will be enrolled at a dose of 4 x 1013 vg/kg, and an additional three may be enrolled at this dose or the previously tested high dose of 6 x 1013 vg/kg. In the up to six additional patients, the requirement for prophylactic corticosteroids has been removed and the threshold for starting therapeutic corticosteroids has been increased. Safety and efficacy data from these patients will inform the Phase 2b study planned to begin in the second half of 2017. "We are pleased that MHRA has approved the resumption of enrollment of the BMN 270 study, as well as the study amendments. We believe that the amendments will allow us to optimize the design of a robust Phase 2b clinical trial, which potentially could support an accelerated approval by health authorities," said Hank Fuchs, M.D., Chief Medical Officer at BioMarin. "We are grateful to the patients who are participating in this current study, and are encouraged by the results so far for this Phase 1/2 trial."

  • 27

    Oct

  • 06

    Nov

  • 29

    Nov

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

BMRN BioMarin
$86.87

-1.08 (-1.23%)

09/19/16
RAJA
09/19/16
NO CHANGE
RAJA
Outperform
Sarepta approval opens up revenue stream for BioMarin, says Raymond James
Raymond James analyst Christopher Raymond noted that the FDA approval of Sarepta's (SRPT) eteplirsen for the treatment of exon 51 skipping amenable Duchenne's muscular dystrophy opens up an "unexpected potential revenue stream" for BioMarin (BMRN), which he said currently holds a "dominant patent position" on Exon 51 skipping therapies. The analyst, who thinks BioMarin may stand to benefit from Sarepta's news, keeps an Outperform rating on BioMarin shares.
09/21/16
09/21/16
NO CHANGE

RBC identifies top biotech takeover candidates
RBC Capital identified the following names as its top potential takeover candidates in the biotech space: ARIAD (ARIA), Spark Therapeutics (ONCE), BioMarin (BMRN), Aerie Pharmaceuticals (AERI), Intra-Cellular (ITCI), TESARO (TSRO), Incyte (INCY), Sarepta (SRPT), and Puma Biotechnology (PBYI). The firm thinks that investors are underestimating the positive impact that M&A will have on biotech stock prices.
09/21/16
LEER
09/21/16
NO CHANGE
LEER
Market Perform
Previous PTAB ruling remains overhang on Sarepta eteplirsen, says Leerink
Leerink analyst Joseph Schwartz notes that Sarepta (SRPT) has announced favorable Patent Trial and Appeal Board of the U.S. Patent and Trademark Office decisions in favor of its exon 51 and 53 composition of matter patent interference cases against BioMarin (BMRN). However, he points out that these rulings are subject to appeal and a previous ruling from the U.S. Patent Trial and Appeal Board, or PTAB, in favor of BioMarin's method of use patent remains an overhang on the commercialization of Sarepta's eteplirsen. The analyst reiterates a Market Perform rating on Sarepta's shares.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).

TODAY'S FREE FLY STORIES

TSLA

Tesla

$376.40

4.16 (1.12%)

, P

Pandora

$7.77

0.26 (3.46%)

14:31
06/22/17
06/22
14:31
06/22/17
14:31
Periodicals
Tesla held talks with labels on music streaming service, Recode says »

Tesla (TSLA) has held…

TSLA

Tesla

$376.40

4.16 (1.12%)

P

Pandora

$7.77

0.26 (3.46%)

AAPL

Apple

$145.87

0.86 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

TSLA

Tesla

$384.73

8.27 (2.20%)

14:26
06/22/17
06/22
14:26
06/22/17
14:26
Periodicals
Tesla in talks with labels on creating streaming service, Recode says 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

ESV

Ensco

$5.13

0.055 (1.08%)

14:25
06/22/17
06/22
14:25
06/22/17
14:25
Options
Ensco call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVO

Novo Nordisk

$43.77

0.06 (0.14%)

14:22
06/22/17
06/22
14:22
06/22/17
14:22
Hot Stocks
Novo Nordisk says CHMP endorses EU label update of Saxenda »

Novo Nordisk announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$32.60

0.18 (0.56%)

14:21
06/22/17
06/22
14:21
06/22/17
14:21
Hot Stocks
Roche reports FDA approval of Rituxan Hycela »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 13

    Jul

$NSD

NASDAQ Market Internals

14:17
06/22/17
06/22
14:17
06/22/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
06/22/17
06/22
14:16
06/22/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAVG

Navigators

$52.80

-0.4 (-0.75%)

14:15
06/22/17
06/22
14:15
06/22/17
14:15
Initiation
Navigators initiated  »

Navigators initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

WDR

Waddell & Reed

$19.55

0.73 (3.88%)

, IVZ

Invesco

$35.07

0.27 (0.78%)

14:14
06/22/17
06/22
14:14
06/22/17
14:14
Recommendations
Waddell & Reed, Invesco, T. Rowe Price analyst commentary  »

Waddell & Reed…

WDR

Waddell & Reed

$19.55

0.73 (3.88%)

IVZ

Invesco

$35.07

0.27 (0.78%)

TROW

T. Rowe Price

$73.04

-0.3 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

RAD

Rite Aid

$3.15

-0.0443 (-1.39%)

, WBA

Walgreens Boots Alliance

$78.12

-0.18 (-0.23%)

14:13
06/22/17
06/22
14:13
06/22/17
14:13
Periodicals
Capitol Forum says Lipsky reccomends blocking Rite Aid deal, Bloomberg says »

The FTC is said to be set…

RAD

Rite Aid

$3.15

-0.0443 (-1.39%)

WBA

Walgreens Boots Alliance

$78.12

-0.18 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

MDRX

Allscripts

$12.19

0.11 (0.91%)

14:10
06/22/17
06/22
14:10
06/22/17
14:10
Options
Allscripts attracts bullish option flow as shares see strength »

Allscripts attracts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLD

Sears

$6.43

-0.37 (-5.44%)

14:05
06/22/17
06/22
14:05
06/22/17
14:05
Options
Sears call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNK

Cinemark

$38.39

-1.43 (-3.59%)

, RGC

Regal Entertainment

$20.46

-0.3 (-1.45%)

14:02
06/22/17
06/22
14:02
06/22/17
14:02
Hot Stocks
Analyst says sell Cinemark on weaker theater outlook, VOD threat »

Credit Suisse downgraded…

CNK

Cinemark

$38.39

-1.43 (-3.59%)

RGC

Regal Entertainment

$20.46

-0.3 (-1.45%)

AMC

AMC Entertainment

$22.70

-0.35 (-1.52%)

IMAX

IMAX

$23.40

-0.8 (-3.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLM

Martin Marietta

$228.17

1.08 (0.48%)

14:01
06/22/17
06/22
14:01
06/22/17
14:01
Hot Stocks
Martin Marietta announces Lloyd to retire as CFO »

Martin Marietta Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

AAL

American Airlines

$48.43

0.4 (0.83%)

13:59
06/22/17
06/22
13:59
06/22/17
13:59
Periodicals
American Air CEO: Not particularly excited about Qatar overture, Bloomberg says »

According to a letter to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 26

    Jun

  • 07

    Jul

HMC

Honda

$27.57

0.004 (0.01%)

, NSANY

Nissan

$19.09

-0.02 (-0.10%)

13:55
06/22/17
06/22
13:55
06/22/17
13:55
Periodicals
Honda, Nissan, Toyota to support Takata through recovery, Nikkei reports »

Japanese auto giants…

HMC

Honda

$27.57

0.004 (0.01%)

NSANY

Nissan

$19.09

-0.02 (-0.10%)

TM

Toyota

$105.48

0.92 (0.88%)

TKTDY

Takata

$2.25

0.45 (25.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

SNCR

Synchronoss

$10.65

0.47 (4.62%)

, T

AT&T

$38.22

0.065 (0.17%)

13:53
06/22/17
06/22
13:53
06/22/17
13:53
Recommendations
Synchronoss, AT&T, Verizon analyst commentary  »

Synchronoss comments on…

SNCR

Synchronoss

$10.65

0.47 (4.62%)

T

AT&T

$38.22

0.065 (0.17%)

VZ

Verizon

$45.54

0.125 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 27

    Jul

DIS

Disney

$104.39

-0.41 (-0.39%)

13:49
06/22/17
06/22
13:49
06/22/17
13:49
Hot Stocks
Ron Howard takes over director duties on 'Han Solo' film »

Lucasfilm announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

SPWR

SunPower

$7.68

0.17 (2.26%)

, FSLR

First Solar

$37.23

1.78 (5.02%)

13:47
06/22/17
06/22
13:47
06/22/17
13:47
Hot Stocks
Solar stocks surge after Trump floats idea of sun-powered border wall »

Solar stocks soared…

SPWR

SunPower

$7.68

0.17 (2.26%)

FSLR

First Solar

$37.23

1.78 (5.02%)

JKS

JinkoSolar

$20.55

1.15 (5.93%)

CSIQ

Canadian Solar

$13.99

0.94 (7.20%)

JASO

JA Solar

$6.41

0.14 (2.23%)

TSLA

Tesla

$376.40

4.16 (1.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

  • 02

    Oct

AZN

AstraZeneca

$35.50

0.62 (1.78%)

13:45
06/22/17
06/22
13:45
06/22/17
13:45
Options
AstraZeneca call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

PCRFY

Panasonic

$13.65

0.123 (0.91%)

13:37
06/22/17
06/22
13:37
06/22/17
13:37
Periodicals
Panasonic aims to double cumulative dishwasher sales by 2026, Nikkei says »

Panasonic said it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:35
06/22/17
06/22
13:35
06/22/17
13:35
General news
NY Fed accepted $195.14 B in daily reverse repos »

NY Fed accepted $195.14 B…

SNCR

Synchronoss

$10.65

0.47 (4.62%)

, VZ

Verizon

$45.52

0.11 (0.24%)

13:30
06/22/17
06/22
13:30
06/22/17
13:30
Earnings
Synchronoss sees 'negligible' 2017 revenue impact from AT&T 'Locker' shut down »

In a business update…

SNCR

Synchronoss

$10.65

0.47 (4.62%)

VZ

Verizon

$45.52

0.11 (0.24%)

T

AT&T

$38.22

0.07 (0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 27

    Jul

PPC

Pilgrim's Pride

$23.33

-0.07 (-0.30%)

13:30
06/22/17
06/22
13:30
06/22/17
13:30
Options
Meaty put activity in Pilgrims Pride »

Meaty put activity in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$243.51

0.56 (0.23%)

, SPX

S&P 500

13:25
06/22/17
06/22
13:25
06/22/17
13:25
Technical Analysis
Technical View: S&P 500 in small very short-term bullish price channel »

Heading into afternoon…

SPY

SPDR S&P 500 ETF Trust

$243.51

0.56 (0.23%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.